Aeromics

Executive Summary

Aeromics is a clinical-stage pharmaceutical company developing first-in-class aquaporin-4 (AQP4) inhibitors for severe neurological disorders, with lead candidate AER-271 targeting cerebral edema in acute ischemic stroke. Founded on Nobel Prize-winning research, the company addresses a significant unmet medical need where no approved pharmacologic therapy exists to reduce brain swelling after stroke. AER-271, an intravenous AQP4 inhibitor, has demonstrated proof-of-concept in preclinical studies and is advancing through clinical development. The company is privately held, based in San Diego, and focuses on translating fundamental water channel biology into life-saving therapeutics for neurocritical care.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Clinical Trial Top-Line Data (AER-271 in Ischemic Stroke)40% success
• Q2 2026Series B or Strategic Partnership Financing50% success
• Q3 2026FDA Meeting or Fast Track Designation for AER-27160% success